Rossari Biotech Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹698 Cr +19.1% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
RB

Rossari Biotech Ltd

Q4 FY25Chemicals & Petrochemicals

Rossari Biotech Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹580Cr
+22.6% YoY
+13.1% QoQ
Net profit
₹34Cr
0% YoY
+6.3% QoQ
Margin
12%
−1 pp YoY
−1 pp QoQ
Price₹502
Market cap₹2.8K Cr
P/E18.5

The short version

Rossari Biotech targets mid-teens percentage growth in overall business revenue, with an annual growth rate around 15% (Page 4, 6). Consumer businesses expected to be profitable by FY27, with expansion fully online and higher Ethylene Oxide (EO) availability (Sunil Chari).

From Rossari Biotech Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Rossari Biotech targets mid-teens percentage growth in overall business revenue, with an annual growth rate around 15% (Page 4, 6).
  • Ethoxylation capacity expansion expected to be commissioned by Q2 FY26, supporting growth in key segments (Page 4).
  • HPPC (Home and Personal Care) business anticipated to grow in low double digits (~10%) in FY26, with some mid-teens growth possible due to new non-EO products (Page 6).
  • Consumer and Institutional businesses grew 67% YoY to Rs. 299 crore in FY25 and expected to scale meaningfully in coming years, aiming for profitability by FY27 (Pages 4, 13).

2 more points from Rossari Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Rossari Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Ongoing CAPEX focused on Ethoxylation capacity expansion expected to be operational by Q2 FY26.
  • Additional CAPEX of Rs. 192 crore approved for phased expansions at subsidiaries Unitop Chemicals, Tristar Intermediates (Rs. 97 crore), and Rossari Biotech (Rs. 95 crore), to be commissioned by Q4 FY26.
  • New expansions emphasize non-Ethylene Oxide (EO) products, backward integration including Esters and Monomers, and new chemistries in the Mellitic space.
  • Investments include scaling up biosurfactant production with a large fermenter addition.
  • R&D expansion underway, including a new center in Mumbai and increased staffing for innovation and future product development.
  • Aim to enhance production capabilities, supply reliability, operational efficiency, and support scalable, sustainable growth.

2 more points from Rossari Biotech Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Rossari Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant insights include: - The company completed expansions expected to be commissioned by Q2 and Q4 FY26, aimed at supporting growth and enhancing supply reliability. - Demand remains strong globally with exports growing by 27%, presence in over 70 countries. - The company is cautious with Bangladesh customers due to currency issues but is exploring other geographies like Southeast Asia, Egypt, and Turkey to grow textile exports.

2 more points from Rossari Biotech Ltd's call on order book

Create a free account to keep reading this call

Rossari Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Rossari Biotech Ltd Q4 FY25 results — key figures

Rossari Biotech Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue580473+22.6%513+13.1%
Operating profit (EBITDA)6964+7.8%65+6.2%
Operating margin12%13%-1 pp13%-1 pp
Profit before tax4846+4.3%42+14.3%
Net profit (PAT)34340%32+6.3%
EPS (₹)6.226.18+0.6%5.73+8.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹698 Cr, net profit ₹39 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Atul (Q4 FY25)

    Consolidated revenue from operations for 2024-25: ₹5,583 cr, 18% increase YoY from ₹4,726 cr in 2023-24 (Page 36). Key concall takeaways from Atul Ltd's Q4…

  • Vidhi Specialty (Q4 FY25)

    109.5 Crs, up 40.2% YoY (from Rs. Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Chemcon Speciality Chemicals (Q4 FY25)

    54.9 Crs, down 8% YoY from Rs. Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Valiant Organics (Q4 FY25)

    Q4-FY25 revenue from operations (consolidated) was INR 2,038 million, a 15.3% year-on-year (YoY) increase from INR 1,768 million in Q4-FY24 (Page 12 and 10)…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Rossari Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Rossari Biotech Ltd Q4 FY25 results?

Rossari Biotech targets mid-teens percentage growth in overall business revenue, with an annual growth rate around 15% (Page 4, 6). Consumer businesses expected to be profitable by FY27, with expansion fully online and higher Ethylene Oxide (EO) availability (Sunil Chari).

What is Rossari Biotech Ltd share price analysis?

Rossari Biotech Ltd currently shows a neutral. The stock trades at a P/E of 18.5 with a market cap of ₹2,786 Cr. Investors should review the full earnings analysis for detailed insights.

Is Rossari Biotech Ltd planning capital expenditure?

Ongoing CAPEX focused on Ethoxylation capacity expansion expected to be operational by Q2 FY26.

Keep Rossari Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.